BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1985700)

  • 1. Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia.
    Stiff PJ; Schulz WC; Bishop M; Marks L
    Blood; 1991 Jan; 77(2):355-62. PubMed ID: 1985700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia.
    Wisniewski D; Strife A; Arlin Z; Knowles R; Lambek C; Gulati S; McHendry B; McKenzie S; Clarkson B
    Leukemia; 1989 Jun; 3(6):446-52. PubMed ID: 2657231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells.
    Roy DC; Griffin JD; Belvin M; Blättler WA; Lambert JM; Ritz J
    Blood; 1991 Jun; 77(11):2404-12. PubMed ID: 2039821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia.
    Robertson MJ; Soiffer RJ; Freedman AS; Rabinowe SL; Anderson KC; Ervin TJ; Murray C; Dear K; Griffin JD; Nadler LM
    Blood; 1992 May; 79(9):2229-36. PubMed ID: 1571539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination.
    Lemoli RM; Gasparetto C; Scheinberg DA; Moore MA; Clarkson BD; Gulati SC
    Blood; 1991 Apr; 77(8):1829-36. PubMed ID: 2015406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of in vitro inhibition of etoposide (VP16) on leukemic and normal myeloid, erythroid clonogenic cells.
    Lagneaux L; Marie JP; Delforge A; Socquet M; Thevenin D; Zittoun R; Stryckmans P
    Exp Hematol; 1989 Aug; 17(7):843-6. PubMed ID: 2753092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures.
    La Russa VF; Griffin JD; Kessler SW; Cutting MA; Knight RD; Blattler WA; Lambert JM; Wright DG
    Exp Hematol; 1992 May; 20(4):442-8. PubMed ID: 1373688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture.
    Grant S; Bhalla K; Arlin Z; Howe CW
    Exp Hematol; 1990 Jan; 18(1):41-8. PubMed ID: 2298268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
    Duzkale H; Pagliaro LC; Rosenblum MG; Varan A; Liu B; Reuben J; Wierda WG; Korbling M; McMannis JD; Glassman AB; Scheinberg DA; Freireich EJ
    Biol Blood Marrow Transplant; 2003 Jun; 9(6):364-72. PubMed ID: 12813444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical evaluation of anti-lacto-N-fucopentaose III (CD15) monoclonal antibodies for ex vivo bone marrow purging in acute myeloid leukemia.
    Guyotat D; Shi ZH; Campos L; Rabat M; Bonnier S; Poncelet P; Laurent JC; Fiere D
    Bone Marrow Transplant; 1990 Dec; 6(6):385-90. PubMed ID: 1982926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM.
    Krehmeier C; Zühlsdorf M; Büchner T; Hiddemann W
    Haematol Blood Transfus; 1990; 33():129-32. PubMed ID: 2323625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GM-CSF enhances sensitivity of leukemic clonogenic cells to long-term low dose cytosine arabinoside with sparing of the normal clonogenic cells.
    De Witte T; Muus P; Haanen C; Van der Lely N; Koekman E; Van der Locht A; Blankenborg G; Wessels J
    Behring Inst Mitt; 1988 Aug; (83):301-7. PubMed ID: 3071344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro chemoseparation of leukemic cells from murine bone marrow using VP16-213: importance of stem cell assays.
    Stiff PJ; Koester AR
    Exp Hematol; 1987 Mar; 15(3):263-8. PubMed ID: 3545881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dye-mediated photolysis is capable of eliminating drug-resistant (MDR+) tumor cells.
    Lemoli RM; Igarashi T; Knizewski M; Acaba L; Richter A; Jain A; Mitchell D; Levy J; Gulati SC
    Blood; 1993 Feb; 81(3):793-800. PubMed ID: 8427970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deoxycytidine preferentially protects normal versus leukemic myeloid progenitor cells from cytosine arabinoside-mediated cytotoxicity.
    Bhalla K; MacLaughlin W; Cole J; Arlin Z; Baker M; Graham G; Grant S
    Blood; 1987 Aug; 70(2):568-71. PubMed ID: 3607288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-trans retinoic acid potentiates megakaryocyte colony formation: in vitro and in vivo effects after administration to acute promyelocytic leukemia patients.
    Visani G; Zauli G; Tosi P; Ottaviani E; Gibellini D; Manfroi S; Celeghini C; Pagliarini C; Bassini A; Tura S
    Leukemia; 1994 Dec; 8(12):2183-7. PubMed ID: 7528859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.
    Balaian L; Ball ED
    Exp Hematol; 2005 Feb; 33(2):199-211. PubMed ID: 15676214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivity profiles of leukemic myeloblasts with monoclonal antibodies directed to sialosyl-Le(x) and other lacto-series type 2 chain antigens:absence of reactivity with normal hematopoietic progenitor cells.
    Muroi K; Suda T; Nojiri H; Ema H; Amemiya Y; Miura Y; Nakauchi H; Singhal A; Hakomori S
    Blood; 1992 Feb; 79(3):713-9. PubMed ID: 1370643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.
    Motta MR; Mangianti S; Rizzi S; Ratta M; Campanini E; Fortuna A; Fogli M; Tura S; Lemoli RM
    Exp Hematol; 1997 Nov; 25(12):1261-9. PubMed ID: 9357970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.
    Lemoli RM; Gulati SC
    Exp Hematol; 1990 Oct; 18(9):1008-12. PubMed ID: 2397748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.